Takeda announces u.s. fda grants priority review for new drug application for mobocertinib (tak-788) as a treatment for egfr exon20 insertion+ metastatic non-small cell lung cancer

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food and drug administration (fda) has granted priority review for the company's new drug application (nda) for mobocertinib (tak-788) for the treatment of adult patients with epidermal growth factor receptor (egfr) exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mnsclc), as detected by an fda-approved test, w
TAK Ratings Summary
TAK Quant Ranking